Our research and discovery initiatives, driven by our proprietary chemical technology, have yielded novel compounds targeting significant bacterial threats. These compounds are now in the clinical trial phase of development.

XERAVA (eravacycline)



  • A fully synthetic tetracycline antibiotic in phase 1 clinical testing
  • Development program targets respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens
  • Potent activity in vitro against Gram-negative and Gram-positive pathogens associated with respiratory tract infections
  • National Institutes of Health's National Institute of Allergy and Infectious Diseases funding supports preclinical development and phase 1 study
  • Granted Qualified Infectious Disease Product and Fast Track designations by the U.S. Food and Drug Administration for both IV and oral formulations
  • Positive safety and pharmacokinetic data from IV single-ascending and multiple-ascending dose studies


  • A fully synthetic tetracycline antibiotic in phase 1 clinical development
  • Potent activity in vitro against multidrug-resistant Gram-negative pathogens
  • Phase 1 multiple-ascending dose study ongoing
  • Selected to receive $4 million in funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to support development

Investigational Products

Multiple investigational compounds are currently in the discovery phase. Our proprietary technology for tetracycline synthesis gives access to a broad range of molecules that would be inaccessible by semisynthetic methods and provides a powerful engine for the discovery and potential development of new tetracycline drugs.


Please enter a valid email address.


Please enter a valid email address.

Share information about Tetraphase


Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.